Capstan 医疗保证110万美元 用于推进机器人心脏阀门外科技术 Capstan Medical secures $110M to advance robotic heart valve surgery technology.

Capstan Medical公司是更换心脏阀的机器人系统开发商,已获得C系列资金1.1亿美元。 Capstan Medical, a developer of robotic systems for heart valve replacement, has secured $110 million in Series C funding. 这项投资由Eclipse领导,包括新投资者和现有投资者,将支持公司努力推广最起码的侵入性外科手术技术,以取代甲状腺和三震阀门。 The investment, led by Eclipse and including new and existing investors, will support the company's efforts to advance minimally invasive surgical techniques for replacing mitral and tricuspid valves. Capstan 的目标是在明年初进行其首个人类二尖瓣手术，并计划在 2028 年之前将其设备提交给 FDA 批准。 Capstan aims to conduct its first human mitral valve procedure early next year and plans to submit its device for FDA approval by 2028.